A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
This study is investigating a new treatment called VHB937 for people recently diagnosed with Amyotrophic Lateral Sclerosis (ALS). Researchers want to find out if VHB937 is safe and effective in helping slow down the progression of the disease. Participants will receive either VHB937 or a placebo (a dummy drug) for about 40 weeks, without knowing which one they are getting. The study will look at how the treatment affects their ability to do daily activities, their breathing, and any side effects they experience. This includes a careful review of their overall health throughout the treatment period and beyond, to ensure their safety and monitor any changes.
Auf einen Blick
Worum geht es in dieser Studie?
This research study is trying to understand more about a new medication called VHB937 for people who have been diagnosed with Amyotrophic Lateral Sclerosis, often called ALS or motor neurone disease. ALS is a condition that affects the nerves in the brain and spinal cord, leading to muscle weakness over time. The main goal of this particular study is to see if VHB937 can help improve the lives of people with early-stage ALS, and if it's safe to use.
In this study, some people will receive VHB937, and others will receive a 'placebo'. A placebo is like a dummy treatment that looks exactly like the real medication but doesn't contain any active drug. This helps the researchers truly understand if any changes seen are due to VHB937 itself. Neither you nor your study doctor will know whether you are receiving VHB937 or the placebo, which is a standard way to get unbiased results in medical research.
Your health will be carefully watched throughout the study. The researchers will be looking at things like your ability to do everyday tasks, how your breathing is, and whether you experience any unwanted side effects. Participating in a study like this helps doctors learn more about new treatments, potentially leading to better options for people with ALS in the future. It's a way for you to contribute to medical knowledge and potentially help others down the line.
Wichtige Erkenntnisse
- This study is testing a new drug called VHB937 for early-stage ALS.
- It aims to see if VHB937 is safe and can improve daily activities and breathing.
- Participants will receive either VHB937 or a harmless dummy drug (placebo).
- Your health will be closely monitored by a medical team.
- You might help future patients with ALS by taking part.
- Die Teilnahme ist freiwillig, und Sie können jederzeit zurücktreten.
Wer könnte berechtigt sein?
To be able to join this study, you need to be at least 18 years old. You must have a confirmed diagnosis of ALS from the study doctors, and your symptoms should have started within the last two years. The study is looking for people whose ALS symptoms are not yet severe, meaning you can still do most daily activities.
You might be suitable if you haven't started any treatment for ALS yet, or if you are already on an approved ALS treatment and your dose has been stable. You'll also need to be able to breathe out a reasonable amount of air, at least 60% of what is expected for someone your age, height, and gender.
However, some things would mean you can't join. For example, if you've recently taken part in another drug trial, have serious heart, liver, or kidney problems, or certain blood disorders, this study might not be right for you. Also, if you have other serious health conditions like certain cancers, uncontrolled diabetes, HIV, Hepatitis, or severe breathing difficulties, you might not be able to participate. The study team will carefully check all these details to make sure it's safe for you to take part.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- Sind Sie 18 Jahre alt oder älter?
- Have you been diagnosed with ALS by a doctor?
- Did your ALS symptoms start within the last two years?
- Are your ALS symptoms currently mild?
- Do you have stable breathing (not severe difficulties)?
- Are you not currently in another drug trial for ALS?
Was beinhaltet die Teilnahme?
If you decide to take part in this study, you will first go through some initial checks to see if you are suitable. If you are, you'll then be assigned to either receive VHB937 or a placebo – you won't know which one. You will take the study medication for about 40 weeks (around 10 months). During this time, you'll have regular visits to the study clinic for check-ups, where doctors will monitor your ALS symptoms, overall health, and any side effects. You'll likely fill out questionnaires about your daily activities and have breathing tests. After the main 40-week period, you may have the option to continue receiving VHB937 in an 'open-label extension' where everyone knows they are getting the active drug. The total duration of your involvement, including follow-up, will be clearly explained to you.
Potenzielle Risiken und Vorteile
Locations (74)
- Universität von Kalifornien San DiegoVerifizierte PostleitzahlLa Jolla, Vereinigte Staaten
- Loma Linda University HealthVerifizierte PostleitzahlLoma Linda, United States
- Keck Medical Center USCVerifizierte PostleitzahlLos Angeles, Vereinigte Staaten
- UC San Francisco Medical CenterVerifizierte PostleitzahlSan Francisco, Vereinigte Staaten
- Universität von MiamiVerifizierte PostleitzahlMiami, Vereinigte Staaten
- Orlando Health Clinical TrialsVerifizierte PostleitzahlOrlando, Vereinigte Staaten
- Emory University School of MedicineVerifizierte PostleitzahlAtlanta, Vereinigte Staaten
- University Of Kansas Medical CenterVerifizierte PostleitzahlKansas City, Vereinigte Staaten
- Massachusetts General HospitalVerifizierte PostleitzahlBoston, Vereinigte Staaten
- University of Nebraska Medical CenterVerifizierte PostleitzahlOmaha, United States
- Lange Neurology PCVerifizierte PostleitzahlNew York, Vereinigte Staaten
- University of Rochester Medical CenterVerifizierte PostleitzahlRochester, Vereinigte Staaten
Häufige Fragen
What is ALS?
ALS (Amyotrophic Lateral Sclerosis) is a progressive condition that affects nerve cells in the brain and spinal cord, leading to muscle weakness and wasting over time.
What is VHB937?
VHB937 is a new medication being tested in this study to see if it can help people with ALS. We don't know yet if it will be effective or safe.
Was ist ein Placebo?
A placebo is a 'dummy' treatment that looks like the real medication but contains no active drug. It helps researchers compare the new medicine to not having it, to see if it makes a difference.
Werde ich wissen, ob ich das Medikament oder das Placebo erhalte?
No, you and your study doctor will not know whether you are receiving VHB937 or the placebo during the main part of the study. This is called a 'blinded' study and helps make the results fair.
Kann ich die Studie jederzeit verlassen?
Yes, you can leave the study at any point, for any reason. Your decision will not affect your ongoing medical care.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.